Today: 20 May 2026
Woodside Energy stock edges higher as oil dips; investors watch Jan 28 update
6 January 2026
1 min read

Woodside Energy stock edges higher as oil dips; investors watch Jan 28 update

Sydney, Jan 6, 2026, 17:59 AEDT — Market closed

Woodside Energy Group Ltd (WDS.AX) shares ended 0.8% higher at A$23.52 on Tuesday, after trading between A$23.31 and A$23.59. The stock had fallen about 1.4% a day earlier, after touching an intraday high of A$24.01.

The move matters because Woodside’s share price remains tightly tethered to shifts in crude oil and liquefied natural gas (LNG), the super-chilled fuel shipped by tanker. Energy traders have been recalibrating supply expectations, keeping day-to-day volatility elevated.

That sensitivity is coming back to the fore as investors look ahead to Woodside’s next production update later this month, a report that can reset expectations for costs and capital spending. With the stock stuck in the mid-A$23 range, small changes in the oil tape have translated into quick reversals.

The broader S&P/ASX 200 index closed down 0.5% at 8,682 points and slipped below its 50-day moving average, a trend gauge watched by technical traders. The energy sector rose 0.6%.

Brent crude futures, the global oil benchmark, fell 0.2% to $61.62 a barrel in Asia, while U.S. West Texas Intermediate was down 0.3% at $58.13. “There will be more pressure on an already over-supplied market,” Marex analyst Ed Meir said, as traders weighed whether political change in Venezuela could eventually lift output. Reuters

For Woodside, Tuesday’s low near A$23.31 sits as the first support level on traders’ screens. Monday’s A$24.01 intraday high is the nearest resistance.

Woodside last week finalised a binding deal with Turkey’s state energy company BOTAS to supply about 5.8 billion cubic metres of LNG over up to nine years from 2030, converting a non-binding agreement reached in September.

But the stock’s recovery leaves little cushion if crude prices extend their decline on expectations of rising supply. Any downside surprise on project costs, production or unplanned outages in the next update would likely amplify moves.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Why Commonwealth Bank (ASX:CBA) shares fell 3% as Australia’s CPI test nears
Previous Story

Why Commonwealth Bank (ASX:CBA) shares fell 3% as Australia’s CPI test nears

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms
Next Story

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms

Go toTop